Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 153
- Registration Number
- NCT02352753
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
The Efficacy of Denosumab in Active Crohn's Disease
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 2
- Registration Number
- NCT02321280
- Locations
- 🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada
Denosumab for Treating Periprosthetic Osteolysis.
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- Olof Skoldenberg
- Target Recruit Count
- 20
- Registration Number
- NCT02299817
- Locations
- 🇸🇪
Danderyd Hospital, Stockholm, Sweden
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT02176382
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 152
- Registration Number
- NCT02132026
- Locations
- 🇬🇧
Clinical Research Facility University of Edinburgh, Edinburgh, United Kingdom
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
- Conditions
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 595
- Registration Number
- NCT02129699
- Locations
- 🇦🇹
Univ. Klinik für Innere Medizin V, Innsbruck, Austria
🇦🇹KH der Elisabethinen Linz, Linz, Austria
🇦🇹AKH Wien, Wien, Austria
Effect of Denosumab on Cellular Biomarkers in the Human Breast
- Conditions
- Interventions
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 82
- Registration Number
- NCT02099461
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Elizabeth Shane
- Target Recruit Count
- 33
- Registration Number
- NCT02049866
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Creighton University, Omaha, Nebraska, United States
Denosumab China Phase III Study
- Conditions
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 486
- Registration Number
- NCT02014467
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Denosumab Administration After Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01983475
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, New York, United States
🇺🇸Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.